Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre, open label, interventional, comparative, phase I study to identify a
safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva
product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who
have Primary Open Angle Glaucoma.